ethyl [(7-{[2-(3-chlorophenyl)-2-hydroxyethyl]amino}-5,6,7,8-tetrahydronaphthalen-2-yl)oxy]acetate hydrochloride | 929601-09-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl [(7-{[2-(3-chlorophenyl)-2-hydroxyethyl]amino}-5,6,7,8-tetrahydronaphthalen-2-yl)oxy]acetate hydrochloride
• 英文别名: N-[(2R)-7-ethoxycarbonylmethoxy-1,2,3,4-tetrahydronaphth-2-yl]-(2R)-2-(3-chlorophenyl)-2-hydroxyethanamine hydrochloride；ethyl 2-[[7-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]-5,6,7,8-tetrahydronaphthalen-2-yl]oxy]acetate;hydron;chloride
• CAS: 929601-09-2
• 化学式: C₂₂H₂₆ClNO₄*ClH
• 分子量: 440.367
• InChiKey: NQIZCDQCNYCVAS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.88
• 重原子数：
  29
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  67.8
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating non-inflammatory gastrointestinal tract disorders
  申请人：Fraser Oliver Matthew

  公开号：US20050113421A1

  公开（公告）日：2005-05-26

  A method is provided for using Cav2.2 subunit calcium channel modulators, particularly thiazolidinone, oxazolidinone, and imidazolone derivatives, to treat non-inflammatory gastrointestinal tract disorders.

  提供了一种方法，用于使用Cav2.2亚单位钙通道调节剂，特别是噻唑啉酮、噁唑啉酮和咪唑啉酮衍生物，来治疗非炎症性胃肠道疾病。
• INDOLE DERIVATIVE
  申请人：DAINIPPON PHARMACEUTICAL CO., LTD.

  公开号：EP0801059A1

  公开（公告）日：1997-10-15

  An indole derivative of the formula: wherein R1 is lower alkoxy, lower alkoxycarbonyl-lower alkoxy, carboxy-lower alkoxy , lower alkoxycarbonyl, phenyl-lower alkoxy, lower alkyl being optionally substituted by hydroxy, di-lower alkylaminosulfonyl, etc., R2 is hydrogen, halogen, lower alkoxy, lower alkoxycarbonyl-lower alkoxy, carboxy-lower alkoxy, etc., R3 is hydrogen or lower alkyl, R4 is halogen or trifluoromethyl, R5 is lower alkyl, or a salt thereof, these compounds being potent β3-adrenergic receptor-stimulating agent with excellent adrenoceptor selectivity, and being useful in the prophylaxis or treatment of obesity or diabetes mellitus.

  一种吲哚衍生物，其式如下 其中 R1 是低级烷氧基、低级烷氧羰基-低级烷氧基、羧基-低级烷氧基、低级烷氧羰基、苯基-低级烷氧基、任选被羟基取代的低级烷基、二低级烷基氨基磺酰基等，R2 是氢、卤素、低级烷氧基、低级烷氧羰基-低级烷氧基、羧基-低级烷氧基等、R3是氢或低级烷基，R4是卤素或三氟甲基，R5是低级烷基，或其盐，这些化合物是强效的β3-肾上腺素能受体刺激剂，具有良好的肾上腺素受体选择性，可用于预防或治疗肥胖症或糖尿病。
• PHENYLETHANOLAMINE COMPOUNDS USEFUL AS BETA3 AGONIST, PROCESS FOR PRODUCING THE SAME, AND INTERMEDIATES IN THE PRODUCTION OF THE SAME
  申请人：TOKYO TANABE COMPANY LIMITED

  公开号：EP0940387A1

  公开（公告）日：1999-09-08

  The present invention relates to phenylethanolamine compounds represented by general formula [I]:    (where R1 represents hydrogen or halogen; R2 represents hydrogen, hydroxy, lower alkoxy, lower alkoxy substituted with one or two lower alkoxycarbonyl or carboxy groups, lower alkoxy substituted with lower alkylaminocarbonyl which may be substituted with lower alkoxy, lower alkoxy substituted with cyclic aminocarbonyl of 4 to 6 carbon atoms, lower alkoxycarbonyl or carboxy; R3 represents hydrogen, hydroxy, lower alkoxy or lower alkoxy substituted with one or two lower alkoxycarbonyl or carboxy groups; R2 and R3 may be bonded to each other to form methylenedioxy substituted with carboxy or lower alkoxycarbonyl; and m and n are 0 or 1), and their pharmacologically acceptable salts, which have a potent β 3 adrenergic stimulating effect and high β 3 adrenergic receptor selectivity, as well as to processes for their production and intermediates in their production.

  本发明涉及通式[I]代表的苯乙醇胺化合物： (其中 R1 代表氢或卤素；R2 代表氢、羟基、低级烷氧基、被一个或两个低级烷氧羰基或羧基取代的低级烷氧基、被可被低级烷氧基取代的低级烷氨基羰基取代的低级烷氧基、被 4 至 6 个碳原子的环氨基羰基、低级烷氧羰基或羧基取代的低级烷氧基；R3 代表氢、羟基、低级烷氧基或被一个或两个低级烷氧基羰基或羧基取代的低级烷氧基；R2 和 R3 可相互键合形成被羧基或低级烷氧基羰基取代的亚甲基二氧基；m 和 n 为 0 或 1），以及它们的药理上可接受的盐（具有强效的 β 3 肾上腺素能刺激作用和高β 3 肾上腺素能受体选择性），以及它们的生产工艺和生产过程中的中间体。
• Kinin antagonists for treating bladder dysfunction
  申请人：Jerini AG

  公开号：EP1741444A1

  公开（公告）日：2007-01-10

  The present invention is related to the use of a kinin receptor antagonist for the manufacture of a medicament for the treatment and/or prevention of bladder dysfunction, whereby the kinin receptor is selected from the group comprising B1 and B2 receptors.

  本发明涉及使用激肽受体拮抗剂制造治疗和/或预防膀胱功能障碍的药物，其中激肽受体选自包括 B1 和 B2 受体的组。
• Methods for treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators
  申请人：Dynogen Pharmaceuticals, Inc.

  公开号：EP1721607A1

  公开（公告）日：2006-11-15

  A method is provided for using α2δ subunit calcium channel modulators or other compounds that interact with the α2δ calcium channel subunit in combination with one or more compounds with smooth muscle modulatory effects to treat and/or alleviate the symptoms associated with painful and non-painful lower urinary tract disorders in normal and spinal cord injured patients. According to the present invention, α2δ subunit calcium channel modulators include GABA analogs (e.g. gabapentin and pregabalin), fused bicyclic or tricyclic amino acid analogs of gabapentin, and amino acid compounds. Compounds with smooth muscle modulatory effects include antimuscarinics, β3 adrenergic agonists, spasmolytics, neurokinin receptor antagonists, bradykinin receptor antagonists, and nitric oxide donors.

  本发明提供了一种使用α2δ亚基钙通道调节剂或其他与α2δ钙通道亚基相互作用的化合物与一种或多种具有平滑肌调节作用的化合物联合治疗和/或缓解正常人和脊髓损伤患者疼痛性和非疼痛性下尿路障碍相关症状的方法。根据本发明，α2δ亚基钙通道调节剂包括 GABA 类似物（如加巴喷丁和普瑞巴林）、加巴喷丁的融合双环或三环氨基酸类似物以及氨基酸化合物。具有平滑肌调节作用的化合物包括抗心绞痛药、β3 肾上腺素能激动剂、解痉药、神经激肽受体拮抗剂、缓激肽受体拮抗剂和一氧化氮供体。